Shire Pharmaceutical
CAMBRIDGE, Massachusetts and BASINGSTOKE, England, March 1, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced it will actively support Rare
Disease Day across the world by generating media coverage in many countries
to raise awareness and understanding of rare diseases.
CAMBRIDGE, Massachusetts, February 26, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announced today that the U.S.
CAMBRIDGE, Massachusetts, February 24, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces it has received Fast Track designation
from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement
therapy for Fabry disease.
DUBLIN, February 19, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty
biopharmaceutical company, announces results for the year to December 31,
2009.
CAMBRIDGE, Massachusetts, February 11 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today presented positive results from its first
Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase
alfa, its investigational enzyme replacement therapy for the treatment of
Type 1 Gaucher disease.
